Skip to content
Bored Studies
RecruitingPhase 4

A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

Gila Therapeutics, Inc. · NCT07728383

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 4
Target enrollment
40
US sites recruiting
1
Study start
June 17, 2026
Record last updated
July 27, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study investigates the Topical-Lingual (T-L) delivery of semaglutide, a GLP-1 receptor agonist (GLP-1RA), via an oral liquid emulsion formulation as a Proof-of-Concept for the T-L delivery of metabolic hormones in general. GLP-1 is a gut-derived hormone that induces satiation through hypothalamic pathways.

Being studied: Semaglutide 6 mg liquid emulsion formulation; Wegovy® (semaglutide) Tablet; Placebo liquid emulsion formulation

Conditions: Obesity & Overweight

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Body Mass Index 30 to 45

Exclusion Criteria

  • Type 2 Diabetes Mellitus
  • Multiple Endocrine Neoplasia Type 2
  • Medullary thyroid cancer

Recruiting US locations

  • Clinical Research Institute of Minnesota

    Minneapolis, MN 55402

    Site contact: Gary D Berman, M.D. · 612-333-2200 · gdb@allergy-asthma-docs.com

All weight loss studies in Minnesota →
A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide… (NCT07728383) | Bored Studies